Table 1.
Summary of baseline demographics, medical history, and background/concomitant medications
| Variable | LCZ696 100 or 200 mg bid N = 30 |
|---|---|
| Age, years (mean ± SD) | 62.0 ± 9.3 |
| Male/female | 25 (83.3)/5 (16.7) |
| Body mass index, kg/m2 (mean [min–max]) | 30.66 (22.8–38.9) |
| NYHA | |
| Class II | 17 (56.7) |
| Class III | 13 (43.3) |
| LVEF %, mean (±SD) | 33.6 (4.56) |
| Systolic BP, mm Hg (mean ± SD) | 133.0 ± 14.59 |
| Diastolic BP, mm Hg (mean ± SD) | 79.6 ± 8.36 |
| Medical history (by preferred term) | |
| Heart rate, beats per min (mean ± SD) | 70.3 ± 11.18 |
| Myocardial infarction | 27 (90.0) |
| Arterial Hypertension | 26 (86.7) |
| Atrial fibrillation | 6 (20.0) |
| Diabetes mellitus | 5 (16.7) |
| Renal failure chronic | 3 (10.0) |
| Background/concomitant medications | |
| ACE inhibitorsa | 30 (100.0) |
| Beta‐blocker | 27 (90.0) |
| Spironolactone | 10 (33.3) |
| Furosemide | 19 (63.3) |
| Hydrochlorothiazide | 8 (26.7) |
| Indapamide | 1 (3.3) |
| Digoxin | 4 (13.3) |
| Nifedipine | 5 (16.7) |
| Aspirin | 27 (90.0) |
| Nitrates | 10 (33.3) |
| Statin | 15 (50.0) |
ACE, angiotensin‐converting enzyme; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation.
Data are presented as n (%), unless otherwise specified.
a
Treatment with ACE inhibitors was discontinued before the study initiation.